Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2012-03-29 Regulatory Filings
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2012
Regulatory Filings
2012-03-29 English
FORM 10-Q
Interim / Quarterly Report Q2 2012
2012-02-14 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a securities purchase agreement and the issuance of Series B Convertible Preferred Stock, including details about the conversion terms, dividends, and fees paid to placement agents. It also references prior filings and includes a press release as an exhibit. The document is focused on a financing transaction and capital raising event. It is not an annual or quarterly report, audit report, or earnings release. It is not a proxy, voting result, or management change announcement. The primary subject is the update on capital raising and financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing, not just an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear focus on financing terms and transaction details.
2012-02-09 English
PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus Supplement No. 2' and references a previous Prospectus and Prospectus Supplement. It details the issuance of Series B Convertible Preferred Stock and Common Stock, including terms of conversion, dividend rates, and purchase price. The document is a supplement to a registration statement filed pursuant to Rule 424(b)(3), which is a SEC rule related to prospectus supplements for securities offerings. The content focuses on capital raising activities and terms of the securities offered, indicating it is related to financing and capital structure updates. It is not an annual or quarterly report, audit report, or earnings release. It is not a voting result, management change, or legal proceeding. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4669 characters, which is sufficient to contain substantive information rather than just an announcement. Confidence is high due to clear references to securities issuance and financing terms.
2012-02-08 English
AMENDMENT TO FORM 10-Q
Interim / Quarterly Report Q1 2011
2011-12-10 English
FORM 10-Q
Interim / Quarterly Report Q1 2012
2011-11-14 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.